NASDAQ:DNLI

Denali Therapeutics Stock Forecast

etoro logo Buy DNLI
*Your capital is at risk
$25.98
+0.260 (+1.01%)
At Close: Jul 01, 2026
AI Analysis AI Analysis of DNLI AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment PRO New!
Trading Strategy PRO New!
Add DNLI to Watchlist?
  • Easy Tracking In The Watchlist
PDF

Weaker technical forecast for Denali Therapeutics Inc. as stock downgraded to Hold/Accumulate
(Updated on Jul 01, 2026)

Buy or Hold candidate since Jun 09, 2026 Gain 24.96%

The Denali Therapeutics Inc. stock price gained 1.01% on the last trading day (Wednesday, 1st Jul 2026), rising from $25.72 to $25.98. During the last trading day the stock fluctuated 2.21% from a day low at $25.62 to a day high of $26.18. The price has risen in 7 of the last 10 days and is up by 18.47% over the past 2 weeks. Volume fell on the last day by -747 thousand shares and in total, 1 million shares were bought and sold for approximately $30.52 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock has broken the wide and strong rising the short-term trend up and an even stronger rate of rising is indicated. For any reaction back there will now be support on the roof on the current trend broken at $23.28, a level that may pose a second chance to hit a runner. According to fan-theory $26.26 will be the next possible trend-top level and thereby pose a resistance level that may not be broken at the first attempt.

DNLI Signals & Forecast

The Denali Therapeutics Inc. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $25.35 and $21.35. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Tuesday, May 19, 2026, and so far it has risen 43.46%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely.

Support, Risk & Stop-loss for Denali Therapeutics Inc. stock

Denali Therapeutics Inc. finds support from accumulated volume at $25.57 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.565 between high and low, or 2.21%. For the last week, the stock has had daily average volatility of 3.43%.

The Denali Therapeutics Inc. stock is extremely overbought on RSI14 (89). Normally this may pose a good selling opportunity but since the stock has broken the trend up, the chance for a major correction due to high RSI is very small as the stock will find support at the trend broken.

Our recommended stop-loss: $25.27 (-2.72%) (This stock has high daily movements and this gives high risk. The RSI14 is 89 and this increases the risk substantially. There is a buy signal from a pivot bottom found 29 days ago.)

Trading Expectations (DNLI) For The Upcoming Trading Day Of Thursday 2nd

For the upcoming trading day on Thursday, 2nd we expect Denali Therapeutics Inc. to open at $25.93, and during the day (based on 14 day Average True Range), to move between $25.44 and $26.52, which gives a possible trading interval of +/-$1.08 (+/-4.23%) up or down from last closing price. If Denali Therapeutics Inc. takes out the full calculated possible swing range there will be an estimated 4.23% move between the lowest and the highest trading price during the day.

With no resistance above and support from accumulated volume @ $25.57, some $0.410 (1.58%) from the current price of $25.98, our system finds the risk reward attractive.

Is Denali Therapeutics Inc. stock A Buy?

Denali Therapeutics Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Hold candidate.

Current score: 0.000 Hold/Accumulate Downgraded

Zero in score indicates that our system is expecting high volatility and risk for the following trading day. Given the latest developments, we cannot determine the next direction as it may go both ways.

Predicted Fair Opening Price

Predicted fair opening price on July 2, 2026 - $25.93 ( 0.212%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* eToro
*Your capital is at risk

DNLI Performance

Trading levels for DNLI

StockInvest.us
Full Access. No Commitment. 7 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 10 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 26.49 1.96%
R2 26.27 1.13%
R1 26.14 0.619%
Price 25.98
S1 25.71 -1.04%
S2 25.58 -1.56%
S3 25.36 -2.39%

Accumulated Volume Support & Resistance Levels

Level Price
R3 0 -
R2 0 -
R1 0 -
Price 25.98
S1 25.57 -1.58%
S2 20.41 -21.44%
S3 19.62 -24.48%

FAQ

What is the symbol for Denali Therapeutics Inc. Stock and on which exchange is it traded?
The symbol for Denali Therapeutics Inc. is DNLI and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Denali Therapeutics Inc. Stock?
Denali Therapeutics Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Hold candidate.

How to buy Denali Therapeutics Inc. Stock?
Denali Therapeutics Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Denali Therapeutics Inc. Stock.

What's the current price of Denali Therapeutics Inc. Stock?
As of the end of day on the Jul 01, 2026, the price of an Denali Therapeutics Inc. (DNLI) share was $25.98.

What is the 52-week high and low for Denali Therapeutics Inc. Stock?
The 52-week high for Denali Therapeutics Inc. Stock is $26.36 and the 52-week low is $12.58.

What is the market capitalization of Denali Therapeutics Inc. Stock?
As of the Jul 01, 2026, the market capitalization of Denali Therapeutics Inc. is 4.123B.

When is the next earnings date for Denali Therapeutics Inc.?
The upcoming earnings date for Denali Therapeutics Inc. is Aug 10, 2026.
Click to get the best stock tips daily for free!
ABOUT DENALI THERAPEUTICS INC.
Denali Therapeutics
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for ...
GOLDEN STAR
Ticker Change Signal Date
SRPT
$17.02
6.93% Jun 29
IIIV
$20.09
9.33% Jun 25
JLL
$299.78
6.19% Jun 24
NMRK
$15.02
3.00% Jun 24
X
XMAX
$8.34
9.71% Jun 24

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE